window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

Stem Cell Therapy

  • Cell & Gene Therapy,Clinical Trials,Pharmaceuticals and therapeutics

    CellProthera publishes Phase 1/2b results of stem cell therapy for post-heart attack patients

    CellProthera has published peer-reviewed results from its phase 1/2b Excellent [...]

    September 14, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy,Research & Development

    PL BioScience opens new headquarters to support growing demand for HPL production

    1,200 m² Aachen facility will enable largest global HPL output [...]

    August 1, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Cell & Gene Therapy

    Celularity and Fountain Life partner to deliver stem cell therapies under new Florida Law

    Celularity and Fountain Life have formed a strategic partnership to [...]

    July 15, 2025
  • Cell & Gene Therapy,Clinical Trials,Drug Development

    Novadip’s autologous cell therapy NVD003 receives RMAT designation for rare pediatric bone disorder

    FDA recognises regenerative approach for congenital pseudarthrosis of the tibia [...]

    June 23, 2025
  • Cell & Gene Therapy

    Cycuria Therapeutics launches with advisory board and major grant funding

    April 28, 2025
  • Clinical Trials

    Novadip’s ‘off-the-shelf’ spine fusion product shows early efficacy and safety in studies

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top